Core Viewpoint - The South African government has announced a ten-year phased national strategy to control foot-and-mouth disease, aiming to restore its "non-immunized disease-free zone" status lost in 2019, with a primary goal of reducing the incidence rate in high-risk provinces by over 70% within 12 months [1] Vaccine Procurement and Production Arrangements - The government plans to import 1 million doses of a trivalent vaccine targeting the South African strains (SAT1, 2, 3) from Argentina's Biogénesis Bagó, with a potential additional order of 5 million doses [2] - Collaboration with the Botswana Vaccine Institute has been established, confirming the availability of SAT2 vaccine raw material [3] - Import approval for the Turkish Dollvet vaccine has been granted [4] - Local production lines at ARC and OBP will commence, initially producing 20,000 doses per week, with plans to scale up to a capacity of 960,000 doses [5] - All vaccines will undergo antigen matching tests at the Pirbright Institute in the UK to ensure efficacy [6] Regional Control Measures - In high-risk provinces (KwaZulu-Natal, Gauteng, Free State, North West): Large-scale vaccination will begin immediately, targeting 100% vaccination in feedlots and dairy farms, 90% in commercial farms, and 80% in public grazing areas [7] - In repeatedly infected areas (Mpumalanga, Limpopo): Vaccination will occur every six months in border hotspots, with wildlife monitoring and targeted immunization around protected areas [7] - In medium-high risk provinces (Eastern Cape): Vaccination in hotspot areas will occur every six months, with the establishment of protective zones and enhanced monitoring at markets and slaughterhouses [8] - In Western Cape: Targeted proactive monitoring has commenced since May 2025 [9] - Northern Cape: Currently the only province reporting no outbreaks [10] Technical Support and Traceability System - A digital heat map through the red meat industry service center will track outbreaks in real-time, monitoring suspected cases within a 10-kilometer radius [11] - Collaboration with the Council for Scientific and Industrial Research will advance livestock identification and traceability systems, enhancing animal movement regulation [12] - Strengthening of the laboratory network led by the Agricultural Research Council's Veterinary Research Institute to improve testing efficiency [13] Collaborative Mechanism - A ministerial advisory group on animal disease control has been formed, bringing together experts from government, academia, and the private sector, reporting directly to the value chain roundtable [14] - The strategy emphasizes the importance of close cooperation between farmers and veterinary departments, urging timely reporting of outbreaks and strict adherence to movement controls [14]

Core Viewpoint - The Chinese vaccine industry is experiencing a severe price war, leading to significant price drops, with some vaccines falling over 90% in price, prompting the China Vaccine Industry Association to call for an end to the price competition to avoid unsustainable costs [1][3]. Group 1: Price Decline and Industry Impact - The price of common vaccines, such as the flu vaccine, has plummeted to about 1/10 of previous prices, with three-valent vaccines previously priced around 60 yuan now being offered as low as 6.5 yuan [3]. - The HPV vaccine has also seen drastic price reductions, with Watson Bio's two-valent HPV vaccine dropping nearly 90% over three years, resulting in significant profit declines for leading vaccine companies, with net profits falling by 70%-90% last year [3][4]. - In the first three quarters of this year, 10 out of 14 publicly listed vaccine companies in China reported profit declines, with over 70% experiencing this trend, and 5 companies are currently operating at a loss [3]. Group 2: Causes of Price Decline - The decline in birth rates has reduced the market size for vaccines, particularly affecting those targeting infants, while competition among manufacturers has intensified, leading to price cuts due to a lack of product differentiation [4]. - The approval of 59 flu vaccine products has resulted in oversupply, with 40% of flu vaccines going unsold and subsequently wasted last year, forcing companies to sell at a loss [4]. Group 3: Long-term Implications for Public Health - While lower vaccine prices may seem beneficial for consumers, the long-term impact on innovation and quality is concerning, as companies may lack the financial incentive to invest in new vaccine development [6]. - The risk of using cheaper raw materials to maintain low prices could compromise vaccine quality, posing a threat to public health [6]. - The industry must balance price reductions with the need for effective and safe vaccines, as the focus should not solely be on affordability but also on health outcomes [6]. Group 4: Strategies for Industry Recovery - Vaccine companies are increasingly looking to expand into emerging markets in Southeast Asia, Latin America, and Africa, with companies like Wantai Biologics significantly increasing their export volumes [8]. - Chinese vaccine firms are moving beyond simple product exports to include technology licensing and localized production, which helps them navigate trade barriers and integrate into local markets [8]. - Achieving international certifications is crucial for these companies, indicating that their quality management systems meet global standards, which is essential for future growth in the global vaccine market projected to reach $86.2 billion by 2032 [8].